Trials / Enrolling By Invitation
Enrolling By InvitationNCT05041309
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Kite, A Gilead Company · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, and anitocabtagene autoleucel in participants of Kite-sponsored interventional studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Axicabtagene Ciloleucel | No investigational product will be administered |
| BIOLOGICAL | Brexucabtagene Autoleucel | No investigational product will be administered |
| BIOLOGICAL | Anitocabtagene autleucel | No investigational product will be administered |
| BIOLOGICAL | KITE-753 | No investigational product will be administered |
| BIOLOGICAL | KITE-197 | No investigational product will be administered |
| BIOLOGICAL | KITE-363 | No investigational product will be administered |
Timeline
- Start date
- 2021-12-15
- Primary completion
- 2040-12-01
- Completion
- 2040-12-01
- First posted
- 2021-09-13
- Last updated
- 2026-02-25
Locations
89 sites across 14 countries: United States, Australia, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05041309. Inclusion in this directory is not an endorsement.